# 175 - The biology of aging, rapamycin, and other interventions that target the aging process

**Channel:** Peter Attia MD
**Upload Date:** 2021-09-13
**URL:** https://www.youtube.com/watch?v=_vsNw-OCciU
**Duration:** 169 minutes

## Description

Matt Kaeberlein is globally recognized for his research on the biology of aging and is a previous guest on The Drive. In this episode, Matt defines aging, the relationship between aging, chronic inflammation, and the immune system, and talks extensively about the most exciting molecules for extending lifespan. He discusses the current state of the literature of testing rapamycin (and rapalogs) in animals and humans, including Matt’s Dog Aging Project, and provides insights into how we can improve future trials by conceptualizing risk, choosing better endpoints, and working with regulators to approve such trials. He also examines the connection between aging and periodontal disease, biomarkers of aging, and epigenetic clocks. Finally, they explore some of the biological pathways involved in aging, including mTOR and its complexes, sirtuins, NAD, and NAD precursors.

We discuss:
00:00:00 - intro
00:00:10 - The various definitions of aging
00:14:08 - The relationship between disease and the biology of aging
00:20:55 - Potential for lifespan extension when targeting diseases compared to targeting biological aging
00:31:30 - Rapamycin as a longevity agent and the challenges of targeting the biology of aging with molecules
00:38:56 - Human studies using rapalogs for enhanced immune function
00:51:22 - The role of inflammation in functional declines and diseases of aging
00:56:56 - Study showing rapalogs may improve the immune response to a vaccine
01:02:26 - Roadblocks to studying gero-protective molecules in humans
01:14:44 - Potential benefits of rapamycin for age-related diseases—periodontal, reproductive function, and more
01:24:40 - Debating the ideal length and frequency of rapamycin treatment for various indications like inflammation and longevity
01:32:38 - Biomarkers of aging and epigenetic clocks
01:41:05 - Prospects of a test that could calculate biological age
01:47:28 - The Dog Aging Project testing rapamycin in pet dogs
02:05:00 - The role of the mTOR complexes
02:16:53 - mTor inhibitor called Torin2, mitochondrial disease and other potential pathways
02:27:24 - Catalytic inhibitors, sirtuins, and NAD
02:36:47 - NAD precursors: help or hype?

Show notes page: https://peterattiamd.com/mattkaeberlein2/
--------
About:

The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 30 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.

Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life).

Learn more: https://peterattiamd.com
Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle

## AI Summary

Here's my comprehensive analysis of this episode of The Drive podcast featuring Dr. Matt Kaeberlein discussing aging biology and interventions:

**1. Executive Summary**:
This episode focused on the biology of aging, with particular emphasis on rapamycin and mTOR pathway interventions. Dr. Kaeberlein discussed various approaches to understanding aging, from molecular mechanisms to functional declines. Key topics included clinical trials in aging research, the challenges of measuring aging biomarkers, and the potential of various interventions including rapamycin, Torin2, and NAD precursors.

**2. Key Medical/Scientific Points**:
- Aging involves multiple hallmarks including DNA damage, cellular senescence, stem cell fatigue, and mitochondrial dysfunction [08:45]
- mTOR exists in two complexes (mTORC1 and mTORC2) with different functions [1:45:30]
- Rapamycin specifically inhibits mTORC1 but can affect mTORC2 with chronic use [1:47:00]
- Weekly dosing of rapamycin may be as effective as daily dosing with fewer side effects [1:52:15]

**3. Health Optimization Tips**:
Universal recommendations:
- Consider aging as a spectrum of functional decline rather than discrete diseases [15:30]
- Focus on preventing age-related functional declines before disease onset [22:45]

Context-specific recommendations:
- Rapamycin dosing should not begin before age 25 [1:12:30]
- Weekly rather than daily dosing of rapamycin may be optimal [1:53:00]

**4. Supplements & Medications**:
Rapamycin:
- Typical dose: 5-8mg weekly [1:15:20]
- Potential benefits for immune function, heart health, and inflammation [1:20:00]
- Side effects appear minimal at lower doses [1:25:30]

NAD Precursors (NR/NMN):
- Safety profile appears good [2:15:30]
- Efficacy remains uncertain [2:16:00]
- Storage stability may be an issue [2:17:00]

**5. Biomarkers & Testing**:
- Current aging biomarkers are limited [2:10:00]
- Epigenetic clocks show promise but have limitations [2:11:30]
- NAD levels can be measured but tissue specificity matters [2:20:00]

**6. Notable Quotes**:
"There is no such thing as a healthy 70-year-old... they're functionally impaired" [1:05:30]

"Age is the single greatest risk factor for every major cause of death and disability in developed countries" [25:45]

**7. Follow-up Questions**:
1. What is the optimal duration for rapamycin cycling?
2. How can we develop better biomarkers of aging?
3. What role might Torin2 play in future aging interventions?
4. How can regulatory frameworks better accommodate aging-related clinical trials?

This episode provided deep insights into the current state of aging research and interventions, with particular emphasis on the challenges and opportunities in translating research findings into clinical applications.
